EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IFN-Based and IFN-Free Direct-Acting Antiviral Drug Treatments for Acquired Hepatitis C Virus in Post-Transplant Recipients

Tomomi Kogiso, Mutsuki Kobayashi, Kuniko Yamamoto, Yuichi Ikarashi, Kazuhisa Kodama, Makiko Taniai, Nobuyuki Torii, Kazunari Tanabe, Hideki Ishida, Shohei Fuchinoue, Hiroto Egawa, Masakazu Yamamoto und 2 weitere

OBM Hepatology and Gastroenterology · 2017

DOI: 10.21926/obm.hg.1702003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift OBM Hepatology and Gastroenterology, 2017. Verfasst von Tomomi Kogiso und 13 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hepatitis C virus (HCV) infection frequently occurs in recipients of liver or kidney transplants (LT/KT). Interferon (IFN)-based therapies are used to treat HCV, but their efficacy is low.

Methods

We report 24 patients who received HCV therapy after LT/KT. Design, Setting, and Participants-Twelve LT and 12 KT recipients (median age, 59 years; 15 males; 21 serological type 1) were enrolled, of whom eight (six with LT) were treated with IFN-based therapy. Twelve received direct-acting antiviral drugs [DAAs; daclatasvir (DCV)/asunaprevir (ASV) therapy] for 24 weeks, seven received sofosbuvir (SOF)/ledipasvir (LDV) for 12 weeks, and one received SOF/ribavirin for 12 weeks.

Results

In two LT patients, HCV resolved spontaneously after LT. Six patients received IFN, of whom one achieved a sustained virological response for 24 or more weeks (SVR) (16.7%), three cases stopped treatment due to side effects (anemia and infection), and two cases relapsed. Five received DCV/ASV, and four received SOF-based DAA, including those with IFN failure. All patients completed treatment with a SVR. Two KT cases were treated with IFN; one was successfully treated and one discontinued treatment due to renal rejection. All cases, including the one IFN failure, achieved a SVR after DAA therapy. Two who received DCV/ASV showed a low estimated glomerular filtration rate (eGFR), and three who received SOF/LDV contained the NS5A mutation. HCV treatment by DAAs was successful in all patients.

Conclusions

DAAs were highly effective and safe in LT/KT recipients who failed IFN-based therapy and had a low eGFR or the NS5A mutation.

Zitieren

APA

Kogiso, T., Kobayashi, M., Yamamoto, K., Ikarashi, Y., Kodama, K., Taniai, M., Torii, N., Tanabe, K., Ishida, H., Fuchinoue, S., Egawa, H., Yamamoto, M., Hashimoto, E., & Tokushige, K. (2017). IFN-Based and IFN-Free Direct-Acting Antiviral Drug Treatments for Acquired Hepatitis C Virus in Post-Transplant Recipients. OBM Hepatology and Gastroenterology. https://doi.org/10.21926/obm.hg.1702003

Vancouver

Kogiso T, Kobayashi M, Yamamoto K, Ikarashi Y, Kodama K, Taniai M, et al. IFN-Based and IFN-Free Direct-Acting Antiviral Drug Treatments for Acquired Hepatitis C Virus in Post-Transplant Recipients. OBM Hepatology and Gastroenterology. 2017. doi:10.21926/obm.hg.1702003

BibTeX
@article{Kogiso2017,
  author = {Kogiso, Tomomi and Kobayashi, Mutsuki and Yamamoto, Kuniko and Ikarashi, Yuichi and Kodama, Kazuhisa and Taniai, Makiko and Torii, Nobuyuki and Tanabe, Kazunari and Ishida, Hideki and Fuchinoue, Shohei and Egawa, Hiroto and Yamamoto, Masakazu and Hashimoto, Etsuko and Tokushige, Katsutoshi},
  title = {IFN-Based and IFN-Free Direct-Acting Antiviral Drug Treatments for Acquired Hepatitis C Virus in Post-Transplant Recipients},
  journal = {OBM Hepatology and Gastroenterology},
  year = {2017},
  doi = {10.21926/obm.hg.1702003}
}
Kostenlos starten →